Literature DB >> 15650221

Bovine herpesvirus 1 VP22 enhances the efficacy of a DNA vaccine in cattle.

Chunfu Zheng1, Lorne A Babiuk, Sylvia van Drunen Littel-van den Hurk.   

Abstract

For this study, the intercellular trafficking ability of bovine herpesvirus 1 (BHV-1) VP22 was applied to improve the efficacy of a DNA vaccine in calves. A plasmid encoding a truncated version of glycoprotein D (tgD) fused to VP22 was constructed. The plasmid encoding tgD-VP22 elicited significantly enhanced and more balanced immune responses than those induced by a plasmid encoding tgD. Furthermore, protection against a BHV-1 challenge was obtained in calves immunized with the plasmid encoding tgD-VP22, as shown by significant reductions in viral excretion. However, less significant protection was observed for animals vaccinated with the tgD-expressing plasmid, correlating with the lower level of immunity observed prechallenge. This is the first report of the use of VP22 as a transport molecule in the context of a DNA vaccine for a large animal species.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650221      PMCID: PMC544085          DOI: 10.1128/JVI.79.3.1948-1953.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Intercellular spread of GFP-VP22.

Authors:  A Aints; M S Dilber; C I Smith
Journal:  J Gene Med       Date:  1999 Jul-Aug       Impact factor: 4.565

2.  Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22.

Authors:  M S Dilber; A Phelan; A Aints; A J Mohamed; G Elliott; C I Smith; P O'Hare
Journal:  Gene Ther       Date:  1999-01       Impact factor: 5.250

3.  Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations.

Authors:  J S Harms; X Ren; S C Oliveira; G A Splitter
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells.

Authors:  B Fang; B Xu; P Koch; J A Roth
Journal:  Gene Ther       Date:  1998-10       Impact factor: 5.250

5.  An inactivated gE-negative marker vaccine and an experimental gD-subunit vaccine reduce the incidence of bovine herpesvirus 1 infections in the field.

Authors:  J C Bosch; M C De Jong; P Franken; K Frankena; J J Hage; M J Kaashoek; M A Maris-Veldhuis; J P Noordhuizen; W H Van der Poel; J Verhoeff; K Weerdmeester; G M Zimmer; J T Van Oirschot
Journal:  Vaccine       Date:  1998 Jan-Feb       Impact factor: 3.641

Review 6.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches.

Authors:  S L Constant; K Bottomly
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

7.  Evaluation of VP22 spread in tissue culture.

Authors:  N Brewis; A Phelan; J Webb; J Drew; G Elliott; P O'Hare
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Immune responses and protection induced by DNA vaccines encoding bovine parainfluenza virus type 3 glycoproteins.

Authors:  S van Drunen Littel-van den Hurk; R P Braun; B C Karvonen; T King; D Yoo; L A Babiuk
Journal:  Virology       Date:  1999-07-20       Impact factor: 3.616

9.  Bovine herpesvirus 1 downregulates the expression of bovine MHC class I molecules.

Authors:  C Nataraj; S Eidmann; M J Hariharan; J H Sur; G A Perry; S Srikumaran
Journal:  Viral Immunol       Date:  1997       Impact factor: 2.257

10.  The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-gamma.

Authors:  Camilo Raggo; Monique Habermehl; Lorne A Babiuk; Philip Griebel
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

View more
  8 in total

Review 1.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

Review 2.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

3.  Characterization of the nuclear localization and nuclear export signals of bovine herpesvirus 1 VP22.

Authors:  Chunfu Zheng; Robert Brownlie; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 4.  Therapeutic HPV DNA vaccines.

Authors:  Ken Lin; Elena Roosinovich; Barbara Ma; Chien-Fu Hung; T-C Wu
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

Review 5.  DNA vaccines and their applications in veterinary practice: current perspectives.

Authors:  K Dhama; Mahesh Mahendran; P K Gupta; A Rai
Journal:  Vet Res Commun       Date:  2008-04-19       Impact factor: 2.459

Review 6.  The Key Role of Nucleic Acid Vaccines for One Health.

Authors:  Anders Fomsgaard; Margaret A Liu
Journal:  Viruses       Date:  2021-02-08       Impact factor: 5.048

Review 7.  Recent Development of Ruminant Vaccine Against Viral Diseases.

Authors:  Sk Mohiuddin Choudhury; XuSheng Ma; Wen Dang; YuanYuan Li; HaiXue Zheng
Journal:  Front Vet Sci       Date:  2021-11-03

8.  VP8, the Major Tegument Protein of Bovine Herpesvirus-1, Is Partially Packaged during Early Tegument Formation in a VP22-Dependent Manner.

Authors:  Soumya Sucharita; Kuan Zhang; Sylvia van Drunen Littel-van den Hurk
Journal:  Viruses       Date:  2021-09-17       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.